

学位授予点年度建设报告 2024

学位授予	位	名称: 昆明医科大学
		代 : 10678

授	学	科	名称: 药学
()	代 : 1007

授	<input checked="" type="checkbox"/> 博 士
	<input type="checkbox"/> 硕 士

2024 年 12 月 31 日

一、学位授予点基本情况

1986 2001
2002
2011 2014
2015
2018 "

2021 ESI 1% 2016
2019 " "

2022 2021
2023
2024

二、学位点年度建设情况

1.

1.1

" "

1.2

— " 30 "

2

2.1

" "

" "

1

1

GCP

2.2

2.2.1

		35	36 45	46 50	51-60			
	25	0	7	8	10	23	24	24
	39	5	21	7	6	19	26	26
	26	12	11	2	1	9	0	0
	0	0	0	0	0	0	0	0
	7	7	0	0	0	4	0	0
	97	24	39	17	17	55	50	50

	22	0	9	1	12	0	3	22
	18	0	8	0	10	0	3	15
	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0
	0	0	0	0	0	0	0	0
	40	0	17	1	22	0	3	37

2 2 2

87

46

41

63

21

50

14

15

8

2 2 3

"

+

"

1

10

20

10

4

/

30

4

1

" " 1

18

2 2 4

2006 7

2009—2024

Adv Sci J Med Chem J Clin

Invest

SCI

I

"

"

"

"

+

2006—

2009

"

"

3

2019

7

1

/

11

2

2

1

1

3

SCI

20

5

"

"

/

SCI

JCR

TOP

3

3

1

2

2

2

2

1

"

"

"

"

			2		1
			1		
			2		20
	Organic Letters		2	2	
3	1				1
	3				
					"
	"	2015			
	2020—2022				
				2023	
				2	
	2		1		Org. Lett.
Chem. Comm.	Green Synth. & Catal.	Adv. Synth. Catal.			
		10		2	
					"
"	2019	6			
		1			1
		2		1	3
				5	
	1			Organic Letters	Organic
Chemistry Frontiers	Bioorganic Chemistry			SCI	15
	4	Natural Products Reports		"	Hot

off the Press"

1

9

1

"

"

6

13

1

3

69

SCI

17

7

1

3

2015-2016

"

"

"

"

10

50

1

4

2016—2017

Á É Æ — Æ P f ! P CD • À

Medicinal Plant Biology

" "

3 L P \$ Y&& 9

" — "

1y

5

10

57

9 2006—2012 α

2015

PØ

"

"

Ä P 0D& PØ "

"

a

2005 2012 2023

- -

2

1

7

12

78

QQ

"

"

Cell Rep EMBO

Mol Med Cell Death & Dis EBioMedicine Clin Cancer Res Cancer Cell

Nat Cell Biol

2031

541

2010 3

1

1

2

3

SCI

7

2016

1

2014

Brain Research

2 3
/ & 6
2011—2013
18
2 3 2
1 1 /
55 SCI 12 3
1
3 2018
"
"
"
/
1 2 1
1
2 4 70 SCI 30
/ 3 / 20

1			1		3	
4				1		50
SCI	18		2	2002—2006		
						"
"						
			1			
		1				1
	"	"	1		30	
/	Oncogene	Biochemical pharmacology				SCI
19		7				
					Front Pharmacol	
3	SCI	J Cell Biochem	10			
2022				Natl Sci Rev	J Med Virol	
		39	SCI	34		

/	SCI	12		20.693
5			2	4
3	4			

2022	"		"	
	Phytomedicine		Front Pharmacol	Thromb Heamost
	6		" COPD	
	"		2021	
3				

					"
		"			
	2		2		
				2	
3		2		1	
16	SCI 6		8	1	4
	2	"	"	1	3
—2018					2017

	10			40	
50		12			
2.3					
		27		90	/
13	/		20	8467	
60.6		8527.6			
99	SCI	71	JCR	8	
20		1	9		8
	1			1	
	10				
			3		1
2.4					
					1200
		10		100	
4		807			35
35		12		721934	
	4		12000		
70%		600 MHz NMR	HRMS		20
34		8	6000		
			3		

2

33

4

4

2 5

" "

" "

2022 101

2022 117

2022 118

2022 119

2023 2

3

/ /	2	/ /	2
/ /	1	/ /	15000
/ /	8000	/ /	12000
/ /	10000	/ /	8000 /
/		8000 / /	5000
/ /	3000	/ /	

" "

2024 102

22

100

95%

" "

3.

3.1

—

5:1
5 3 1
99
84 43 41
15
15% 5
80 54
24 2
3
B
3.2

“

“ ”

”

1

1:200

“ ” “ ”

“ ”

3.3

2024

1

						/
1						36/2
2						36/2
3						36/2

						/
4						36/2
5						36/2
6						27/1.5
7						36/2
8						18/1
9						36/2
10						36/1
11						36/2
12						27/1.5
13						36/2
14						18/1
15						36/2
16						18/1
17						36/1.5
18						36/1
19						36/1.5
20						36/1.5
21						36/1.5
22						36/1.5
23						18/1

						/
24						18/1
25	Radiopharmaceuticals					27/1
26	Scientific writing					27/1

3. 4

2024

3. 5

1.2

3000 27
1 26
1

120 40
20

2024
60 1

3.6

" "

3.6.1

1 2024
2024 8 12—15 2024

214

3

"

"

18

21

17

23

2

2024

2024 7 20—21

2024

486

60

160

52

5

17

"

"

"

"

TDM

3

2024

10

4

2024 10 22

/

50

3.6.2

1

2024 5

2

2024 8 14

3

2024 6 27—28

Jung

" "

Han Sung

4

2024

5

2024 6 17 19

11

3.6.3

1	2024 CACA	" CACA " CACA "	/	2024.06.21-2 024.06.23		5
2		CACA 6 21 23 " "		2024.04.30-2 024.05.08		3

3	2024	60	486 160		2024.07.20-2 024.07.21		60
4	2024				2024.08.12-2 024.08.15		60
5		2022—2024			2024.10.22-2 024.10.24		

3.6.4

									100~200
1	5		20240830						
2	2024		20240905					2022 3	
3	2024		20240905						
4	2024		20240814					COPD	
5	2024		20240905					2	

6	2024		20240905						1
7	ISHR		20240412						ROCK

3.7

100%

2021

CNKI

15%

100%

2024

2

3

1

3.8

2024

3. 8. 1

3. 8. 2

2023 8

2022 9

3. 8. 3

3.9

“ ”

“ ”

“ ”

“ ”

“ ”

APP

“

”

“

”

3.10

1

1

99.5%

3.11

2024 7

99%

100%

86.67%

76.19%

4.

4.1

1

ACE2

ACE2


SARS-CoV-2

" " _____

JCR

1 Proc Natl

Acad Sci USA, 2024, 121(24): e2321619121



1 ACE2

2 BLBC

BLBC

BLBC

KLF5 BLBC

BAP1

KLF5

BAP1-KLF5

BLBC

-β-

lead

LN-439A

KLF5

LN-439A

HCC1806

SUM149PT

BLBC

G2/M

LN-439A

BAP1

KLF5

BAP1

BAP1i

LN-439A 10 mg/kg 20 mg/kg

BLBC

KLF5

LN-439A

KLF5

BAP1

LN-439A


BAP1-KLF5

BLBC

BLBC

JCR

1 Acta Pharmacologica Sinica, 2024: 1-13



2

BAP1

LN-439A

KLF5

3

ZIKV

Orthosiphon wulfenioides


1-6

5 6

EC50 5.0 8.4 μM

5

ZIKV



4

-


Trichophyllae

19

"

"

and Evolution, 2024, 197: 108082



4

Trichophyllae

4.2

1

10

3

1

2

"

	"		10				
				"		YND-01	50
	2024	09	2028	08			
	3						
	2024						
						2024	
08—09			4				
	4.3						
				"	"		
						"	.
"			90				.
						"	"
					"	"	
		9			7		
						"	"
"	"					"	"
					1		2
	"	"				2	

"

"

"

"

4.

5

2025

4